James S. Robertson

Lars Research Institute — United States

Medicine · Health Sciences

49h-index11.6kcitations303works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Influenza Virus Research Studies(59), Viral gastroenteritis research and epidemiology(27), Radiation Dose and Imaging(22), SARS-CoV-2 and COVID-19 Research(20), Virus-based gene therapy research(19)

Publications302 total

New WHO INN for cell-based and gene-based substances: timing, usage, and simplicity
The Lancet·2024
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment
Vaccine·2022· 38 citedOpen Access
International Nonproprietary Names (INN) for novel vaccine substances: A matter of safety
Vaccine·2021· 4 citedOpen Access
The harmonization of World Health Organization International Nonproprietary Names definitions for cell and cell-based gene therapy substances: when a name is not enough
Cytotherapy·2021· 7 citedOpen Access
WHO international non-proprietary names: the need to distinguish COVID-19 vaccines
The Lancet·2021· 1 citedOpen Access
The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform
Vaccine·2020· 60 citedOpen Access
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines
Vaccine·2020· 9 citedOpen Access
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment
Vaccine·2020· 80 citedOpen Access
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
Vaccine·2020· 8 citedOpen Access
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines
Vaccine·2020· 9 citedOpen Access
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines
Vaccine·2020· 10 citedOpen Access
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines
Vaccine·2020· 17 citedOpen Access
Obstructing Chiari Network Facilitating Blood Flow Across a Patent Foramen Ovale Causing Hypoxia
JACC Case Reports·2020· 3 citedOpen Access
OBSTRUCTING CHIARI NETWORK FACILITATING BLOOD FLOW ACROSS A PATENT FORAMEN OVALE CAUSING HYPOXIA
Journal of the American College of Cardiology·2020· 1 cited
SupplementalTable - Closed Genomes
Figshare·2020Open Access
The INN global nomenclature of biological medicines: A continuous challenge
Biologicals·2019· 16 citedOpen Access
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
Vaccine X·2019· 82 citedOpen Access
Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines
Vaccine·2018· 21 citedOpen Access
The Ability of a Non-Egg Adapted (Cell-Like) A(H1N1)pdm09 Virus to Egg-Adapt at HA Loci Other than 222 and 223 and Its Effect on the Yield of Viral Protein
PLoS ONE·2016· 6 citedOpen Access
Studies in the control of the eelworm Heterodera marioni by soil sterilisation
2016
page 1 of 16Next →

Frequent Co-authors

John Wood(8), Diane Major(7), Carolyn Nicolson(5), Janet S. Bootman(4), Robert W. Newman(4), Sylvia Thomas(3), M.T. Hays(3), Roger W. Howell(3), Darrell R. Fisher(3), A.B. Brill(3), Mikhail Matrosovich(3), Robert G. Webster(3), E. P. Cronkite(3), Othmar G. Engelhardt(3), Richard Condit(3), Robert T. Chen(3), J A Siegel(2), B. W. Wessels(2), V. E. Piskarev(2), S. S. Yamnikova(2)